Sunesis Pharmaceuticals Reports Data From Nonclinical Studies Of SNS-032 At The Annual Meeting Of The American Association For Cancer Research
Apr 17th 2008Drug InformationBlood
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
